Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08046052
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Parenteral
01
Overview
PF-08046052 is a potential first-in-class bi-specific antibody drug designed to conditionally activate Vγ9Vδ2 (Vgamma9 Vdelta2) T cells upon crosslinking to the epidermal growth factor receptor (EGFR). This activation triggers potent and preferential killing of EGFR-positive tumor cells. The drug leverages the Gammabody platform developed by LAVA Therapeutics and is being evaluated for its safety, clinical pharmacology, and anti-tumor activity in advanced solid tumors. EGFR is a well-established target over-expressed in multiple solid tumor types including colorectal cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and pancreatic ductal adenocarcinoma (PDAC). PF-08046052 is currently under clinical development by Pfizer under an exclusive worldwide license from LAVA Therapeutics[4][5][6].
- Other names
- PF08046052PF-08046052PF 08046052EGFRd2EGFRd-2EGFRd 2
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on PF-08046052.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08046052.